Robert Copeland

About

Robert Copeland is the President & Chief Scientific Officer at Accent Therapeutics, Inc. in the United States. His research primarily focuses on innovative cancer therapies, particularly involving DHX9 inhibition and small molecule inhibitors targeting RNA modifying enzymes. His recent articles emphasize advancements in treatment modalities for various cancers, including those with BRCA1 or BRCA2 mutations and microsatellite instability. Additionally, he explores the significance of binding kinetics and drug-target interactions in pharmacology.